Legend Healthmaker of AI-enabled ultrasound guidance software, has partnered with Heartbeat Health to provide virtual cardiovascular care.
As part of the collaboration, Caption physicians will perform ultrasounds wherever needed, including patients’ homes. Heartbeat’s virtual cardiologists will then remotely interpret the results and discuss the findings with the patient’s primary care providers.
The new offering builds on earlier work in which Caption and Heartbeat performed echocardiograms in high-risk populations to look for signs of heart failure. The companies will offer the new program as a value-based package to providers, payers and value-based care organizations.
“This is an ideal combination of patient-centric services, which will open up access to life-saving early detection of heart disease and Heartbeat Health’s network of world-class cardiologists and virtual care,” said Caption CEO Steve Cashman in a statement.
“Whether it’s heart wellness for patients with risk factors, outpatient care for patients with non-urgent symptoms, or convenient follow-up echocardiography to help patients avoid costly and complex readmissions, we believe our joint offering will have a profound impact on the quality and cost of cardiac care for millions of patients.
THE BIGGEST TREND
Caption has entered into several partnerships this year. In June, the company announced a collaboration with home provider Portamedic to offer its AI-enabled ultrasounds in patients’ homes and other settings. It is also working with UK-based Ultromics to use its tools in conjunction with Ultromics’ EchoGo deep ultrasound analysis.
Their software can also be used in a portable ultrasonic maker. The new platform of Butterfly Network.
Founded in 2013, Caption’s targeting tool it received De Novo clearance from the FDA in 2020. The company announced a $53 million Series B round later that year. Meanwhile, Heartbeat raised $20 million last year which was based on an $8.2 million Series A from 2020.
Another player in the AI-enabled ultrasound space is ultrasound device maker Exo, which recently announced that it had acquired AI developer Medo. The company plans to integrate AI tools into its platform so more doctors can capture and interpret images.